GAL-021
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528001

CAS#: 1380341-99-0

Description: GAL-021 is a large conductance calcium-activated potassium channel (BKCa-channel) blocker potentially for the treatment of respiratory depression. GAL-021 inhibited KCa1.1 in GH3 cells, and the evoked ventilatory stimulation was attenuated in Slo1 mice lacking the pore-forming α-subunit of the KCa1.1 channel. At a higher concentration of GAL-160 (100 μM), inhibition of the delayed rectifier K(+) current and leak K(+) current were observed.


Price and Availability

Size
Price

25mg
USD 250
200mg
USD 1250
2g
USD 4350
Size
Price

50mg
USD 450
500mg
USD 2150
5g
USD 6450
Size
Price

100mg
USD 850
1g
USD 3250

GAL-021, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 528001
Name: GAL-021
CAS#: 1380341-99-0
Chemical Formula: C11H22N6O
Exact Mass: 254.1855
Molecular Weight: 254.338
Elemental Analysis: C, 51.95; H, 8.72; N, 33.04; O, 6.29


Synonym: GAL-021; GAL 021; GAL021

IUPAC/Chemical Name: 6-(methoxy(methyl)amino)-N2,N4-dipropyl-1,3,5-triazine-2,4-diamine

InChi Key: FJNLCHNQVJVCPY-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16)

SMILES Code: CCCNC1=NC(N(OC)C)=NC(NCCC)=N1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Golder FJ, Dax S, Baby SM, Gruber R, Hoshi T, Ideo C, Kennedy A, Peng S, Puskovic V, Ritchie D, Woodward R, Wardle RL, Van Scott MR, Mannion JC, MacIntyre DE. Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator. Anesthesiology. 2015 Nov;123(5):1093-104. doi: 10.1097/ALN.0000000000000844. PubMed PMID: 26352381.

2: Dallas ML, Peers C, Golder FJ, Baby S, Gruber R, MacIntyre DE. GAL-021 and GAL-160 are Efficacious in Rat Models of Obstructive and Central Sleep Apnea and Inhibit BKCa in Isolated Rat Carotid Body Glomus Cells. Adv Exp Med Biol. 2015;860:361-70. doi: 10.1007/978-3-319-18440-1_41. PubMed PMID: 26303501.

3: McLeod JF, Leempoels JM, Peng SX, Dax SL, Myers LJ, Golder FJ. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113(5):875-83. doi: 10.1093/bja/aeu182. PubMed PMID: 24989775.

4: Roozekrans M, Olofsen E, van der Schrier R, van Gerven J, Peng S, McLeod J, Dahan A. Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Clin Pharmacol Ther. 2015 Jun;97(6):641-9. doi: 10.1002/cpt.99. PubMed PMID: 25704491.

5: Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014 Sep;121(3):459-68. doi: 10.1097/ALN.0000000000000367. PubMed PMID: 25222672.

6: van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014 Sep 4;6:79. doi: 10.12703/P6-79. Review. PubMed PMID: 25343036; PubMed Central PMCID: PMC4173639.

7: Golder FJ, Hewitt MM, McLeod JF. Respiratory stimulant drugs in the post-operative setting. Respir Physiol Neurobiol. 2013 Nov 1;189(2):395-402. doi: 10.1016/j.resp.2013.06.010. Review. PubMed PMID: 23791825.

8: Cotten JF. The latest pharmacologic ventilator. Anesthesiology. 2014 Sep;121(3):442-4. doi: 10.1097/ALN.0000000000000368. PubMed PMID: 25222671; PubMed Central PMCID: PMC4166568.

9: Xie Y, Puscheck EE, Rappolee DA. Effects of SAPK/JNK inhibitors on preimplantation mouse embryo development are influenced greatly by the amount of stress induced by the media. Mol Hum Reprod. 2006 Apr;12(4):217-24. PubMed PMID: 16574700.